Alumis Reports 48-Week Phase 3 Data for Envudeucitinib in Plaque Psoriasis
Envudeucitinib plaque psoriasis: Alumis reports 54% complete skin clearance at 48 weeks in Phase 3 ONWARD3 and plans an NDA in Q4 2026.
Tag: TYK2 inhibitor
Read More